<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972942</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-598</org_study_id>
    <nct_id>NCT04972942</nct_id>
  </id_info>
  <brief_title>Targeted Immunotherapy After Myeloablative TBI-Based Conditioning &amp; AlloHCT in CAYA With High Risk T-Cell ALL &amp; Lymphoma</brief_title>
  <acronym>ALLO-T-DART</acronym>
  <official_title>Phase II Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV&#xD;
      after total body irradiation (TBI)-based myeloablative conditioning and allogeneic&#xD;
      hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA)&#xD;
      with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma&#xD;
      (T-LLy).&#xD;
&#xD;
      Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents,&#xD;
      and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study&#xD;
      will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA&#xD;
      post-HCT treatment and correlate with patient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with dose limiting toxicity (per CTCAE v.5)</measure>
    <time_frame>60 days</time_frame>
    <description>occurrence of any Grade ≥ 3 non hematologic toxicity (per CTCAE v.5) which is probably, or definitely related to daratumumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To measure relapse free survival in patients post HCT and daratumumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>T-cell Acute Lymphoblastic Leukemia</condition>
  <condition>T-Cell Acute Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Daratumumab (DARA) treatment post-HCT 8 mg/kg/dose&#xD;
Induction: DARA 16 mg/kg IV weekly x 8 doses (Weeks 1-8)&#xD;
Consolidation: DARA 16 mg/kg IV every 2 weeks x 8 doses (Weeks 9-24)&#xD;
Maintenance: DARA 16 mg/kg IV every 4 weeks x 5 doses following start of treatment (Weeks 25-44)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.&#xD;
Daratumumab (DARA) treatment post-HCT&#xD;
Induction: DARA 16 mg/kg IV weekly x 8 doses (Weeks 1-8)&#xD;
Consolidation: DARA 16 mg/kg IV every 2 weeks x 8 doses (Weeks 9-24)&#xD;
Maintenance: DARA 16 mg/kg IV every 4 weeks x 5 doses following start of treatment (Weeks 25-44)</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>Darzalex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  0-39yrs&#xD;
&#xD;
          -  T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with&#xD;
             complete response after re-induction therapy&#xD;
&#xD;
          -  Planned allogeneic stem cell transplantation with donor identified&#xD;
&#xD;
          -  Performance status ≥ 60%&#xD;
&#xD;
          -  Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy,&#xD;
             or radiotherapy prior to entering this study&#xD;
&#xD;
          -  Meet organ function requirements&#xD;
&#xD;
          -  Signed IRB approved informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  May not have had a prior autologous or allogenic stem cell transplant&#xD;
&#xD;
          -  May not have uncontrolled, systemic infection at the time of enrollment&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol,&#xD;
             corticosteroids, monoclonal antibodies or human proteins, or their excipients&#xD;
&#xD;
          -  Must not be pregnant or actively breast feeding&#xD;
&#xD;
          -  Seropositive for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Cairo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troy Quigg, DO</last_name>
    <role>Study Chair</role>
    <affiliation>Helen DeVos Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allyson Flower, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Harrison, RN, MSN</last_name>
    <phone>6172857844</phone>
    <email>lauren_harrison@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Morris, RN</last_name>
    <phone>7149645359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

